Get the Stockscreener App
39.00
3.37%
1.27
After Hours:
39.00
Biohaven Ltd Stock (BHVN) Latest News
Nebraska Joins in Settling Kickback Allegations against Biohaven Pharmaceutical Holding Company Ltd. - Rural Radio Network
Nebraska joins in settling kickback allegations against Biohaven - norfolkneradio.com
Pfizer to pay nearly $60M over kickbacks for migraine drug developed by New Haven-based Biohaven - Hartford Business Journal
Nebraska joins in settling kickback allegations against Biohaven Pharmaceutical Holding Company Ltd. - News Channel Nebraska
Nebraska joins multi-state settlement against Biohaven Pharmaceutical for kickback allegations - News Channel Nebraska
Pfizer settles Biohaven kickback claims case for $59.7m - Yahoo Finance
Financial Crime Weekly: Pfizer Pays Nearly $60 Million To Resolve False Claims Allegations, SEC Creates Crypto Task Force - Benzinga
Pfizer settles Biohaven kickback case with DOJ for $60M - MSN
Pfizer settles Biohaven kickback case with DOJ for $60M (PFE:NYSE) - Seeking Alpha
When (BHVN) Moves Investors should Listen - Stock Traders Daily
Cantor Fitzgerald Forecasts Biohaven FY2025 Earnings - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Stock Holdings Raised by ARS Investment Partners LLC - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Insider Stock Buying Reaches US$23.8m On Biohaven - Simply Wall St
Biohaven’s stock surges as treatment slows progress of neurological disorder - MSN
Biohaven (NYSE:BHVN) Trading Down 6.4%Here's What Happened - MarketBeat
Biohaven Refines Epilepsy Trial Design With Patient-Centric Focus - Clinical Leader
Motor Neuron Disease Clinical and Non-Clinical Studies, Key - openPR
Deal Watch: Bausch Companies Set Hectic Pace At J.P. Morgan With Five Deals - News & Insights
Biohaven (NYSE:BHVN) Stock Price Down 6.4%Should You Sell? - MarketBeat
Why Biohaven Ltd. Stocks Are Rising Now - TipRanks
What's Going On With Merus Stock Monday?Biohaven (NYSE:BHVN), Merus (NASDAQ:MRUS) - Benzinga
Biohaven & Merus Team Up to Develop Novel Bispecific ADC Therapies - Contract Pharma
Biohaven Showcases TRAP Degraders at J.P. Morgan Conference - TipRanks
Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire
Merus and Biohaven Partner to Develop Next-Generation Cancer-Fighting ADC Therapies - StockTitan
Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs - The Manila Times
Biohaven (NYSE:BHVN) Shares Gap DownHere's What Happened - MarketBeat
Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PR Newswire
JPMorgan Chase & Co. Increases Stock Position in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Insider Buying: Biohaven Independent Director Bought US$1.0m Of Shares - Yahoo Finance
Long Term Trading Analysis for (BHVN) - Stock Traders Daily
Biohaven Announces Conference Call to Discuss Topline Pivotal St - GuruFocus.com
Biohaven Stock Surges After Director Acquires Shares Worth Over $1M: Retail Sentiment Turns Bullish - MSN
Biohaven (NYSE:BHVN) Shares Gap Up on Insider Buying Activity - MarketBeat
John W. Childs Buys 29,000 Shares of Biohaven Ltd. (NYSE:BHVN) Stock - MarketBeat
Biohaven Ltd. Stocks Surge Amid Positive Developments - TipRanks
Biohaven director John Childs acquires shares worth $1.04 million By Investing.com - Investing.com Nigeria
Biohaven director John Childs acquires shares worth $1.04 million - Investing.com
Biohaven Ltd. (NYSE:BHVN) Receives $63.00 Average Price Target from Brokerages - MarketBeat
Biohaven Enters Oversold Territory (BHVN) - Nasdaq
How To Trade (BHVN) - Stock Traders Daily
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):